IOVANCE BIOTHERAPEUTICS INC

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

IOVA$8.08-1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(In thousands)



· · · Years Ended December 31,
· · 2024 · 2023 · 2022
Cash Flows from Operating Activities · · · ·
Net loss	$(372,177)	$(444,037)	$(395,893)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	109,627	62,625	84,022
Unrealized foreign exchange gains	(175)	70	—
Amortization of intangible assets	21,202	9,849	—
Amortization of right of use asset	10,437	11,710	11,825
Depreciation and amortization of property and equipment	11,967	11,568	9,310
Deferred tax benefit	(2,828)	(3,479)	—
Accretion of discounts and premiums on investments	(10,261)	(3,605)	474
Impairment of long-lived assets	7,355	—	397
Gain on derecognition of lease assets and liabilities	(5,568)	—	—
Changes in assets and liabilities:
Prepaid expenses, other assets and long-term assets	(2,113)	(10,062)	(2,130)
Trade accounts receivable	(69,189)	(149)	—
Inventory	(39,917)	(10,118)	—
Operating lease liabilities	(12,074)	(10,794)	(1,942)
Accounts payable	(7,841)	4,828	5,883
Accrued expenses and other liabilities	8,578	19,774	(4,703)
Net cash used in operating activities	(352,977)	(361,820)	(292,757)

Cash Flows from Investing Activities
Maturities of investments	428,000	285,583	522,696
Purchase of investments	(460,769)	(205,902)	(245,816)
Cash paid for acquisition, including contingent consideration, net of cash acquired	(52,573)	(212,633)	—
Purchase of property and equipment	(11,069)	(22,290)	(20,425)
Net cash used in investing activities	(96,411)	(155,242)	256,455

Cash Flows from Financing Activities
Tax payments related to shares withheld for vested restricted stock units	(12,858)	(2,795)	(2,649)
Proceeds from the issuance of common stock under employee stock purchase plan	2,952	2,410	1,655
Proceeds from the issuance of common stock upon exercise of options	3,266	63	1,642
Vesting of restricted shares issued for services	—
Proceeds from the issuance of common stock, net	397,304	463,281	189,502
Net cash provided by financing activities	390,664	462,959	190,150
Effect of foreign exchange rate changes	(541)	(2,740)
Net increase in cash, cash equivalents and restricted cash	(59,265)	(56,843)	153,848
Cash, Cash Equivalents and Restricted Cash Beginning of Period	181,318	238,161	84,313
Cash, Cash Equivalents and Restricted Cash End of Period	$122,053	$181,318	$238,161

Supplemental disclosure of non-cash investing and financing activities:
Fair value of net assets acquired	$—	$222,637	—
Net unrealized gain on investments	78	940	(301)
Acquisition of property and equipment included in accounts payable and accrued expenses	7,365	4,062	5,985
Intangible asset and deferred tax liability arising from contingent consideration	17,495	—	—
Lease liabilities arising from obtaining right-of-use asset from new leases	2,306	177	553
Lease liabilities arising from obtaining right-of-use asset from lease modifications	(7,833)	1,033	15,304

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.